新冠疫苗接种后长新冠症状的轨迹:社区队列研究
该研究基于英国社区人群队列,纳入28 356名在感染SARS-CoV-2后接种至少一剂腺病毒载体或mRNA新冠疫苗的18-69岁成人,评估接种与长新冠症状的关联。结果显示,第一剂疫苗与长新冠几率初始下降12.8%相关,第二剂与初始下降8.8%及随后每周下降0.8%相关,提示接种后长新冠症状可能持续改善。
要点
- 第一剂疫苗后长新冠几率初始下降12.8%,后续轨迹无显著变化。
- 第二剂疫苗后长新冠几率初始下降8.8%,随后每周下降0.8%。
- 接种与长新冠的关联在不同人群特征、疫苗类型和感染至接种间隔中一致。
核心结论
- 新冠疫苗接种后长新冠症状的几率下降,第二剂后至少在中位67天随访内显示持续改善。
研究设计与样本
- 观察性队列研究,纳入英国社区居住的28 356名18-69岁在SARS-CoV-2感染后接种至少一剂腺病毒载体或mRNA新冠疫苗的成人。
主要发现
- 随访期间6729名参与者(23.7%)至少一次报告任何严重程度的长新冠症状。
- 第一剂疫苗与长新冠几率初始下降12.8%(95%CI -18.6%至-6.6%,P<0.001)相关,后续变化为每周0.3%(95%CI -0.6%至1.2%,P=0.51)。
- 第二剂疫苗与长新冠几率初始下降8.8%(95%CI -14.1%至-3.1%,P=0.003)相关,随后每周下降0.8%(95%CI -1.2%至-0.4%,P<0.001)。
- 未发现社会人口学特征、健康状况、急性新冠住院、疫苗类型或感染至接种时间对上述关联的异质性。
临床怎么用
- 对于感染SARS-CoV-2后未接种疫苗的成人,接种新冠疫苗可能有助于降低长新冠症状的发生几率。
- 第二剂疫苗可能带来长新冠症状的持续改善,但需更长随访确认。
局限性
- 随访时间有限,第二剂后中位随访仅67天,需更长随访评估长期效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate associations between covid-19 vaccination and long covid symptoms in adults with SARS-CoV-2 infection before vaccination. DESIGN: Observational cohort study. SETTING: Community dwelling population, UK. PARTICIPANTS: 28 356 participants in the Office for National Statistics COVID-19 Infection Survey aged 18-69 years who received at least one dose of an adenovirus vector or mRNA covid-19 vaccine after testing positive for SARS-CoV-2 infection. MAIN OUTCOME MEASURE: Presence of long covid symptoms at least 12 weeks after infection over the follow-up period 3 February to 5 September 2021. RESULTS: Mean age of participants was 46 years, 55.6% (n=15 760) were women, and 88.7% (n=25 141) were of white ethnicity. Median follow-up was 141 days from first vaccination (among all participants) and 67 days from second vaccination (83.8% of participants). 6729 participants (23.7%) reported long covid symptoms of any severity at least once during follow-up. A first vaccine dose was associated with an initial 12.8% decrease (95% confidence interval -18.6% to -6.6%, P<0.001) in the odds of long covid, with subsequent data compatible with both increases and decreases in the trajectory (0.3% per week, 95% confidence interval -0.6% to 1.2% per week, P=0.51). A second dose was associated with an initial 8.8% decrease (95% confidence interval -14.1% to -3.1%, P=0.003) in the odds of long covid, with a subsequent decrease by 0.8% per week (-1.2% to -0.4% per week, P<0.001). Heterogeneity was not found in associations between vaccination and long covid by sociodemographic characteristics, health status, hospital admission with acute covid-19, vaccine type (adenovirus vector or mRNA), or duration from SARS-CoV-2 infection to vaccination. CONCLUSIONS: The likelihood of long covid symptoms was observed to decrease after covid-19 vaccination and evidence suggested sustained improvement after a second dose, at least over the median follow-up of 67 days. Vaccination may contribute to a reduction in the population health burden of long covid, although longer follow-up is needed.
引用
- Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. 2022. PMID: 35584816. doi:10.1136/bmj-2021-069676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。